Katie Partyka
Overview
Explore the profile of Katie Partyka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, et al.
Clin Cancer Res
. 2019 Jan;
25(9):2745-2754.
PMID: 30617132
Purpose: The CA19-9 biomarker is elevated in a substantial group of patients with pancreatic ductal adenocarcinoma (PDAC), but not enough to be reliable for the detection or diagnosis of the...
2.
Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, et al.
Sci Rep
. 2017 Jun;
7(1):4020.
PMID: 28642461
Molecular markers to detect subtypes of cancer cells could facilitate more effective treatment. We recently identified a carbohydrate antigen, named sTRA, that is as accurate a serological biomarker of pancreatic...
3.
Sinha J, Cao Z, Dai J, Tang H, Partyka K, Hostetter G, et al.
PLoS One
. 2016 Dec;
11(12):e0167070.
PMID: 27992432
Molecular indicators to specify the risk posed by a pancreatic cyst would benefit patients. Previously we showed that most cancer-precursor cysts, termed mucinous cysts, produce abnormal glycoforms of the proteins...
4.
Reatini B, Ensink E, Liau B, Sinha J, Powers T, Partyka K, et al.
Anal Chem
. 2016 Nov;
88(23):11584-11592.
PMID: 27809484
Glycans are critical to protein biology and are useful as disease biomarkers. Many studies of glycans rely on clinical specimens, but the low amount of sample available for some specimens...
5.
Tang H, Partyka K, Hsueh P, Sinha J, Kletter D, Zeh H, et al.
Cell Mol Gastroenterol Hepatol
. 2016 Mar;
2(2):201-221.e15.
PMID: 26998508
Background And Aims: The CA19-9 antigen is the current best biomarker for pancreatic cancer, but it is not elevated in about 25% of pancreatic cancer patients at a cutoff that...
6.
Haab B, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, et al.
PLoS One
. 2015 Oct;
10(10):e0139049.
PMID: 26431551
The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessing and comparing performance. We present here a reference set of serum and plasma...
7.
Singh S, Pal K, Yadav J, Tang H, Partyka K, Kletter D, et al.
J Proteome Res
. 2015 May;
14(6):2594-605.
PMID: 25938165
The fucose post-translational modification is frequently increased in pancreatic cancer, thus forming the basis for promising biomarkers, but a subset of pancreatic cancer patients does not elevate the known fucose-containing...
8.
Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, et al.
Mol Cell Proteomics
. 2015 Mar;
14(5):1323-33.
PMID: 25733690
The sialyl-Lewis A (sLeA) glycan forms the basis of the CA19-9 assay and is the current best biomarker for pancreatic cancer, but because it is not elevated in ∼25% of...
9.
West M, Partyka K, Feasley C, Maupin K, Goppallawa I, West C, et al.
BMC Biotechnol
. 2014 Dec;
14:101.
PMID: 25479762
Background: γ-Glutamyl transpeptidase 1 (GGT1) is an N-glycosylated membrane protein that catabolizes extracellular glutathione and other γ-glutamyl-containing substrates. In a variety of disease states, including tumor formation, the enzyme is...
10.
Partyka K, Wang S, Zhao P, Cao B, Haab B
Methods Mol Biol
. 2014 Mar;
1105:3-15.
PMID: 24623215
This chapter describes methods for the use of antibody microarrays with rolling-circle amplification (RCA). The methods are divided into three sections. The first section covers antibody preparation and microarray production,...